5 amazing medical predictions for 2024

“SARS-CoV-2 has continually mutated over the course of the pandemic, resulting in variants that differ from the original SARS-CoV-2 virus,” they explain.

The concern now may be about vaccines against these variants.

“My concern is that if variants move in a different direction and current vaccines become obsolete, then we will have to develop new vaccinesor the main antiviral drugs we currently use will become obsolete and we will have to develop new ones,” Al-Ali said.

So, given this scenario, another COVID prediction for 2024 is that new vaccines may become available.

AI against lung cancer

Lung cancer is one of the deadliest types of cancer in the world.. This is partly because this type of cancer is often diagnosed at an advanced stage, so earlier diagnosis may allow for better and more effective treatment of this disease.

2024 could be the year when we see Advances in early diagnosis of lung cancer. And a team of researchers in the United Kingdom is testing an artificial intelligence (AI) system to diagnose this type of cancer using chest X-rays.

The study will involve 150,000 patients in six UK hospitals and is one of 11 clinical trials that the prestigious journal Nature Medicine says will shape medicine in 2024.

“We will complete recruitment in July 2024 and hope to have results in 2024. Our hypothesis, based on our previous studies, is that we can detect lung cancer earlier and reduce diagnostic time by up to 50%“, the researchers told Nature Medicine.

Anti-obesity drugs

Anti-obesity drugs will definitely be revolutionized by 2023, even those that were not originally created for weight control, but which many have used for this purpose, and which are now even in short supply. This is the case, for example, with Ozempic.

In 2024, treating overweight and obesity will continue to be a major focus. medicine, given the excitement surrounding GLP-1-based drugs, which have demonstrated significant results and been named Breakthrough of the Year by Science magazine.

There are high hopes for this type of drug in 2024 and beyond. He GLP-1 “It is an incretin-like hormone that contributes to the control of glucose homeostasis,” states an article in ElSevier.

But also, plays a regulating role in food intakeinducing a feeling of satiety and appears to have beneficial effects in central and peripheral neurodegenerative syndromes.

“In any case, the value of the potential therapeutic role of GLP-1 not only in diabetes, but also in obesity, heart and nerve diseases is a fact that cannot be ignored,” they emphasize.

Now on to what to expect this year: “In 2024, advances in the treatment of obesity and related diseases will continue to be an important topic for the sector. “The enormous valuations of Lilly and Novo Nordisk, leaders in this field, are underpinned by the belief that their drugs will help radically improve the health of vast swathes of the population,” the Evaluate consensus report said. Pharmaceuticals, El Global review.

Treatment of ALS

Patients with Amyotrophic lateral sclerosis (ALS) They have few treatment options for now, but that could change in 2024 or 2025. A new therapeutic alternative against ALS could be approved in Europe soon. This the drug increases the survival rate of patients with ALS and slows the progression of the disease.

We hope to be able to bring the new drug to ALS patients in 2024.— Elena Molina, head of the Spanish Amylyx laboratory developing the drug, told the website “For your health” from the Spanish newspaper La Razón. But how does this medicine work?

“The therapy is a combination of two molecules that were shown in a phase 2 study to slow disease progression on the one hand and increase survival on the other,” he explained.

And he added: “It has been seen that at six months there is a difference of 25% in benefit, that is, in slowing progression and maintaining functionality in those undergoing treatment. rise from six months.”

ALS is a disease that affects the neurons in the brain, brain stem, and spinal cord that control movement.

Skin cancer vaccine

For the vaccine against skin cancer. While it is expected to be available in 2025 with accelerated approval, 2024 will be the make-or-break year.

And later this year, Moderna will conduct a larger “phase three” study involving 1,000 people. confirm approval of skin cancer vaccineAFP reports.

Skin cancer is one of the most common cancers in the world. The American Cancer Society estimates that by 2023, there will be about 97,610 new cases of melanoma diagnosed in the United States and 7,990 people who will die from melanoma.

The skin cancer vaccine has now been placed under accelerated review by the US Food and Drug Administration (FDA) and the European Medicines Agency.

But that’s not all: Moderna announced that it is testing an mRNA vaccine against lung cancer and is studying other types of cancer.


More content from Urgente24

Banco Nación offers 12 interest-free installments: how to take advantage

Calendar for 2024: holidays and long weekends for “vacation”

Attention monotributists: AFIP reveals updates

Japan: Daihatsu (Toyota) reveals 30 years of lies

Intern at TN DNU: Strong crossover between studio and chronicler

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button